1
|
Reggiani G, Boaro MP, Menzato F, De Bon E, Bertomoro A, Casonato A, Lucente F, Fortino C, Sartori M, Steffan A, Martella M, D'Agnolo M, Sainati L, Colombatti R. Early-onset indicators of a hypercoagulable state and clinical complications in a cohort of children with sickle cell trait. Pediatr Blood Cancer 2024; 71:e30971. [PMID: 38553897 DOI: 10.1002/pbc.30971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 01/31/2024] [Accepted: 03/08/2024] [Indexed: 04/24/2024]
Abstract
Adults with sickle cell trait (SCT) have a procoagulant state with increased risk of thromboembolism, but limited data are available for children. We compared the coagulation profile of children with SCT, different sickle cell disease (SCD) genotypes, and healthy controls. Compared to controls and similarly to HbSC patients, 41 SCT children (mean age 6.85 years; 20 males; 88% Africans) had a characteristic procoagulant profile: higher levels of factor VIII, von Willebrand factor (VWF) Ag and CBA, D-dimer; lower levels of ADAMTS 13 activity, ADAMTS13 activity: VWFAg, plasminogen activator inhibitor, tissue plasminogen activator. Moreover, 13/41 had clinical complications of SCD, five requiring hospitalization.
Collapse
Affiliation(s)
- Giulia Reggiani
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Maria Paola Boaro
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Federica Menzato
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Emiliano De Bon
- UOC General Medicine, Cittadella's Hospital, Cittadella, Italy
| | - Antonella Bertomoro
- Department of Medicine, Internal Medicine 1 Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Alessandra Casonato
- Department of Medicine, Internal Medicine 1 Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Fabrizio Lucente
- Department of Medicine, Internal Medicine 1 Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Cecilia Fortino
- Department of Medicine, Internal Medicine 1 Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - MariaTeresa Sartori
- Department of Medicine, Internal Medicine 1 Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Agostino Steffan
- Department of Diagnostic Laboratory and Cellular Therapy, Centro Riferimento Oncologico, Aviano, Italy
| | - Maddalena Martella
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Mirco D'Agnolo
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Laura Sainati
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| | - Raffaella Colombatti
- Department of Women's and Child's Health, Pediatric Hematology-Oncology Unit, Azienda Ospedaliera-Università di Padova, Padua, Italy
| |
Collapse
|
2
|
Alessi MC, Coxon C, Ibrahim-Kosta M, Bacci M, Voisin S, Rivera J, Greinacher A, Raster J, Pulcinelli F, Devreese KMJ, Mullier F, McCormick AN, Frontroth JP, Pouplard C, Sachs UJ, Diaz I, Bermejo N, Camera M, Fontana P, Bauters A, Stepanian A, Cozzi MR, Sveshnikova AN, Faille D, Hollon W, Chitlur M, Casonato A, Lasne D, Lavenu-Bombled C, Fiore M, Hamidou B, Hurtaud-Roux MF, Saultier P, Goumidi L, Gresele P, Lordkipanidzé M. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost 2023; 21:2596-2610. [PMID: 37331519 DOI: 10.1016/j.jtha.2023.05.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 05/23/2023] [Accepted: 05/24/2023] [Indexed: 06/20/2023]
Abstract
BACKGROUND Light transmission aggregation (LTA) is used widely by the clinical and research communities. Although it is a gold standard, there is a lack of interlaboratory harmonization. OBJECTIVES The primary objective was to assess whether sources of activators (mainly adenosine diphosphate [ADP], collagen, arachidonic acid, epinephrine, and thrombin receptor activating peptide6) and ristocetin contribute to poor LTA reproducibility. The secondary objective was to evaluate interindividual variability of results to appreciate the distribution of normal values and consequently better interpret pathologic results. METHODS An international multicenter study involving 28 laboratories in which we compared LTA results obtained with center-specific activators and a comparator that we supplied. RESULTS We report variability in the potency (P) of activators in comparison with the comparator. Thrombin receptor activating peptide 6 (P, 1.32-2.68), arachidonic acid (P, 0.87-1.43), and epinephrine (P, 0.97-1.34) showed the greatest variability. ADP (P, 1.04-1.20) and ristocetin (P, 0.98-1.07) were the most consistent. The data highlighted clear interindividual variability, notably for ADP and epinephrine. Four profiles of responses were observed with ADP from high-responders, intermediate-responders, and low-responders. A fifth profile corresponding to nonresponders (5% of the individuals) was observed with epinephrine. CONCLUSION Based on these data, the establishment and adoption of simple standardization principles should mitigate variability due to activator sources. The observation of huge interindividual variability for certain concentrations of activators should lead to a cautious interpretation before reporting a result as abnormal. Confidence can be taken from the fact that difference between sources is not exacerbated in patients treated with antiplatelet agents.
Collapse
Affiliation(s)
- Marie-Christine Alessi
- Laboratory of Hematology, Centre de référence des pathologies plaquettaires, C2VN, INRAE, INSERM, Aix Marseille Université, Marseille, France.
| | - Carmen Coxon
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United Kingdom
| | - Manal Ibrahim-Kosta
- Laboratory of Hematology, Centre de référence des pathologies plaquettaires, C2VN, INRAE, INSERM, Aix Marseille Université, Marseille, France
| | - Monica Bacci
- Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Sophie Voisin
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - José Rivera
- Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, Instituto Murciano De Investigación Biosanitaria, IMIB-Arrixaca, Murcia, Spain
| | - Andreas Greinacher
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany
| | - Johannes Raster
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany
| | - Fabio Pulcinelli
- Department of Experimental Medicine, Sapienza University of Rome, Roma, Italy
| | - Katrien M J Devreese
- Department of Diagnostic Sciences, Coagulation Laboratory, Ghent University Hospital, Ghent University, Ghent, Belgium
| | - Francois Mullier
- Namur Thrombosis and Hemostasis Center, CHU UCLouvain Namur, Université Catholique de Louvain, Yvoir, Belgium
| | - Aine N McCormick
- Haemostasis and Thrombosis Laboratory, Viapath Analytics, St Thomas' Hospital, London, United Kingdom
| | - Juan Pablo Frontroth
- Laboratorio de Hemostasia y Trombosis, Hospital de Pediatría "Prof. Dr. Juan P. Garrahan," Buenos Aires, Argentina
| | - Claire Pouplard
- Department of Hemostasis, University Hospital of Tours, University of Tours, Tours, France
| | - Ulrich J Sachs
- Department of Thrombosis and Haemostasis, Giessen University Hospital, Giessen, Germany
| | - Isabelle Diaz
- Laboratory of Hematology, University Hospital of Montpellier, Montpellier, France
| | - Nuria Bermejo
- Servicio de Hematología, Hospital San Pedro de Alcántara, Complejo Hospitalario Universitario de Cáceres, Cáceres, Spain
| | - Marina Camera
- Centro Cardiologico Monzino, Istituto di Ricerca e Cura a Carattere Scientifico, Milan, Italy
| | - Pierre Fontana
- Division of Angiology and Haemostasis, Geneva University Hospitals, and Geneva Platelet Group, Faculty of Medicine, Geneva, Switzerland
| | - Anne Bauters
- Hemostasis Unit, Hospital University Center Lille, Lille, France
| | - Alain Stepanian
- Hematology Laboratory and Thrombosis Unit, Université Paris Cité, Hospital Group Lariboisière-Fernand Widal, Assistance Publique-Hôpitaux de Paris AP-HP, Paris, France
| | - Maria R Cozzi
- Immunopathology and Cancer Biomarkers Unit Centro di Riferimento Oncologico di Aviano, Aviano, Italy
| | - Anastasia N Sveshnikova
- Hemostasis Research Department, Dmitry Rogachev Pediatric Hematology and Immunology Hospital, Moscow, Russia
| | - Dorothée Faille
- Département d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris AP-HP, Centre Hospitalo-Universitaire CHU Bichat-Claude Bernard, Paris, France
| | - Wendy Hollon
- Jeanne M. Lusher Special Coagulation Laboratory, Children's Hospital of Michigan, Wayne State University, Detroit, Michigan, USA
| | - Meera Chitlur
- Central Michigan University, Jeanne M. Lusher Special Coagulation Laboratory, Children's Hospital of Michigan, Detroit, Michigan, USA
| | - Alessandra Casonato
- Department of Medicine, University of Padua Medical School, First chair of Internal Medicine, Padua, Italy
| | - Dominique Lasne
- Laboratoire d'Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France
| | - Cécile Lavenu-Bombled
- Service Hématologie Biologique, Centre de ressources et compétences de la filière de santé des maladies Hémorragiques constitutionnelles MHEMO, Centre Hospitalo-Universitaire CHU Bicêtre, Assistance Publique-Hôpitaux de Paris, Faculté de médecine Paris Saclay, Le Kremlin-Bicêtre, France
| | - Mathieu Fiore
- Bordeaux University Hospital, Laboratory of Hematology, Centre de Reference des Pathologies Plaquettaires Pessac, France
| | - Bello Hamidou
- Laboratory of Hematology, Centre de référence des pathologies plaquettaires, C2VN, INRAE, INSERM, Aix Marseille Université, Marseille, France
| | - Marie-Francoise Hurtaud-Roux
- Assistance Publique-Hôpitaux de Paris, Centre de Reference des Pathologies Plaquettaires, Hôpital Robert Debré, Paris, France
| | - Paul Saultier
- Laboratory of Hematology, Centre de référence des pathologies plaquettaires, C2VN, INRAE, INSERM, Aix Marseille Université, Marseille, France
| | - Louisa Goumidi
- Laboratory of Hematology, Centre de référence des pathologies plaquettaires, C2VN, INRAE, INSERM, Aix Marseille Université, Marseille, France
| | - Paolo Gresele
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy
| | - Marie Lordkipanidzé
- Faculté de Pharmacie, Research Center and The Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada
| |
Collapse
|
3
|
Casonato A, Cozzi MRC, Ferrari S, Rubin B, Gianesello L, De Marco L, Daidone V. The lesson learned from the new c.2547-1G>T mutation combined with p.R854Q:when a type 2N mutation reveals a quantitative von Willebrand factor defect. Thromb Haemost 2022; 122:1479-1485. [DOI: 10.1055/a-1777-6881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Type 2N is a rare von Willebrand disease (VWD) variant involving an impairment in the FVIII carrier function of von Willebrand factor (VWF). It has a phenotype that mimics hemophilia A, and FVIII binding to VWF (VWF:FVIIIB) is tested to differentiate between the two disorders. Type 2N VWF defects may also be associated with quantitative VWF mutations (type 2N/type 1), further complicating the identification of cases.
We report on a new quantitative VWF mutation (c.2547-1G>T) revealed by a p.R854Q type 2N mutation acting as homozygous despite being carried as a heterozygous defect. The proband had near-normal VWF levels (initially ruling out a defective VWF synthesis) and slightly reduced FVIII levels, while a VWF:FVIIIB test showed significantly reduced binding. Routine tests on type 2N homozygotes or heterozygotes combined with quantitative VWF defects in our cohort showed reduced FVIII levels in both groups, but it was only in the former that the FVIII/VWF:Ag ratio was always significantly reduced. The two tests are therefore not enough to identify all forms of type 2N VWD. While relatives of type 2N homozygotes usually have normal FVIII levels and FVIII/VWF:Ag ratios, relatives of type 2N/type 1 may have high FVIII/VWF:Ag ratios, but their VWF:FVIIIB and/or VWF:FVIIIB/VWF:Ag ratios are always low.
Measuring FVIII and VWF levels may therefore suggest type 2N VWD in patients carrying type 2N mutations alone, but not in type 2N combined with quantitative VWF defects. The VWF:FVIIIB test should consequently always be included when exploring VWF function, whatever VWD patient’s phenotype.
Collapse
Affiliation(s)
| | | | - Silvia Ferrari
- Department of Medicine, Universita degli Studi di Padova, Padova, Italy
| | - Beatrice Rubin
- Department of Medicine, Universita degli Studi di Padova, Padova, Italy
| | - Lisa Gianesello
- Department of Medicine, Universita degli Studi di Padova, Padova, Italy
| | | | - Viviana Daidone
- Dept of Medicine, Universita degli Studi di Padova, Padova, Italy
| |
Collapse
|
4
|
Casonato A, Galletta E, Galvanin F, Daidone V. Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival. eJHaem 2021; 2:340-348. [PMID: 35844701 PMCID: PMC9175995 DOI: 10.1002/jha2.196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 03/31/2021] [Accepted: 04/02/2021] [Indexed: 11/09/2022]
Abstract
Type Vicenza von Willebrand disease (VWD) features a von Willebrand factor (VWF) with a very short half‐life, and is classified as a form of type 1 VWD. To test the appropriateness of type Vicenza VWD classification, the main features of 17 patients from eight unrelated families were analysed. They had low VWF antigen levels and function (always below 20 U/dl); ristocetin‐induced platelet aggregation sometimes normal, sometimes reduced/absent (even in the same patient); normal platelet VWF levels; an increased VWF propeptide to VWF antigen ratio (8.74 ± 1.65 vs. normal 1.04 ± 0.28) and a reduced VWF half‐life. Plasma VWF multimer levels were homogeneously reduced, and unusually large VWF multimers were sometimes present. Recombinant p.R1205H VWF showed a normal synthesis, release, function, and multimer pattern, with no ultra‐large VWF multimers. The mathematical model by Galvanin et al. was used to explore the kinetic changes in VWF after DDAVP. It showed that the release, but especially the proteolysis (kproteol 1.0−3 ± 2.5−3 vs. normal 4.5−4 ± 6.4−4) and elimination (kel 1.0−2 ± 5.2−3 vs. normal 1.1−3 ± 6.8−4) of type Vicenza VWF were significantly higher than normal. The increased elimination is consistent with the short half‐life, while the increased proteolysis was unexpected. As a shorter survival of VWF is wholly responsible for the type Vicenza VWD phenotype (VWF synthesis, structure and function are normal), it might be better to classify it as a type 2 VWD (rather than type 1) to emphasise the greater interaction with clearance receptors as a new VWF functional defect.
Collapse
Affiliation(s)
- Alessandra Casonato
- Department of Medicine University of Padua Medical School First Chair of Internal Medicine Padua Italy
| | - Eva Galletta
- Department of Medicine University of Padua Medical School First Chair of Internal Medicine Padua Italy
| | - Federico Galvanin
- Department of Medicine University of Padua Medical School First Chair of Internal Medicine Padua Italy
| | - Viviana Daidone
- Department of Medicine University of Padua Medical School First Chair of Internal Medicine Padua Italy
| |
Collapse
|
5
|
Casonato A, Galletta E, Cella G, Barbon G, Daidone V. Acquired von Willebrand Syndrome Hiding Inherited von Willebrand Disease Can Explain Severe Bleeding in Patients With Aortic Stenosis. Arterioscler Thromb Vasc Biol 2020; 40:2187-2194. [PMID: 32640909 DOI: 10.1161/atvbaha.120.314656] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Aortic stenosis may be complicated by an acquired von Willebrand syndrome that rarely causes significant bleeding, raising the question of why it does so in a few cases. To seek an explanation, we studied 5 severe bleeder aortic stenosis patients in a cohort of 49 patients, using the flowchart for inherited von Willebrand disease. Approach and Results: All 5 patients were lacking in large and intermediate VWF (von Willebrand factor) multimers, 3 had reduced plasma and platelet VWF levels, and none showed PFA100 closure. Two patients (those with most multimers missing) also had a short VWF half-life. Genetic analyses on the 3 patients with reduced platelet VWF levels revealed that one carried both the c.1164C>G and the c.7880G>A mutations, and another carried the c.3390C>T mutation, while the third had one of the 2 VWF alleles relatively less expressed than the other (25% versus 75%). No genetic alterations emerged in the other 2 patients. Successful replacement of the stenotic aortic valve, performed in the 2 patients with VWF mutations, did not correct their abnormal VWF multimer picture-unlike what happened in the aortic stenosis patients without bleeding symptoms. CONCLUSIONS Our findings suggest that acquired von Willebrand syndrome can develop in patients with hitherto-undiagnosed inherited von Willebrand disease. Since von Willebrand disease is the most common bleeding disorder, this possibility should be considered in aortic stenosis patients-especially those with a more severe bleeding history and more disrupted VWF laboratory patterns-because they risk hemorrhage during aortic valve replacement.
Collapse
Affiliation(s)
- Alessandra Casonato
- From the Department of Medicine, First Chair of Internal Medicine (A.C., E.G., G.B., V.D.), University of Padua Medical School, Italy
| | - Eva Galletta
- From the Department of Medicine, First Chair of Internal Medicine (A.C., E.G., G.B., V.D.), University of Padua Medical School, Italy
| | - Giuseppe Cella
- Department of Cardiac, Thoracic and Vascular Sciences (G.C.), University of Padua Medical School, Italy
| | - Giovanni Barbon
- From the Department of Medicine, First Chair of Internal Medicine (A.C., E.G., G.B., V.D.), University of Padua Medical School, Italy
| | - Viviana Daidone
- From the Department of Medicine, First Chair of Internal Medicine (A.C., E.G., G.B., V.D.), University of Padua Medical School, Italy
| |
Collapse
|
6
|
Taverna B, Casonato A, Bezzo F, Galvanin F. A framework for the optimal design of a minimum set of clinical trials to characterize von Willebrand disease. Comput Methods Programs Biomed 2019; 179:104989. [PMID: 31443861 DOI: 10.1016/j.cmpb.2019.104989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 06/18/2019] [Accepted: 07/17/2019] [Indexed: 06/10/2023]
Abstract
BACKGROUND AND OBJECTIVE Von Willebrand disease (VWD) is one of the most severe inherited bleeding disorder in humans, and it is associated with a qualitative and/or quantitative deficiency of von Willebrand factor, a multimeric glycoprotein fundamental in the coagulation process. At present, the diagnosis of VWD is extremely challenging and mostly based on clinical experience. Kinetic models have been recently proposed and applied to help in the diagnosis and characterization of VWD, but the complexity of these models is such that they requires long and stressful clinical tests, such as the desmopressin response test (DDAVP), to achieve a satisfactory estimation of the individual haemostatic parameters. The goal of this paper is to design a minimal set of clinical tests for the identification of akinetic model to decrease the required time and effort for the characterization and diagnosis of VWD. METHODS A model proposed in the literature is used as a building block to develop a new model, where response surface methodologies have been applied to determine a set of explicit correlations linkingkinetic model parameters to basal clinical trials data. Model-based design of experiments techniques are then used to devise optimally informative tests for model validation which are shorter and easier to implement. RESULTS Results show an excellent agreement between the original model for VWD and the new proposed model on representing healthy and VWD subjects. The application of experimental design techniques for model validation shows the possibility to drastically reduce the duration of DDAVP tests from 24 h-3 h by exploiting complementary information from basal clinical tests. CONCLUSIONS Basal clinical tests can be used alongside a time-reduced DDAVP test to validate pharmacokinetic models for a quantitative characterisation of subjects affected by VWD and for a quicker and easier diagnosis of the disease.
Collapse
Affiliation(s)
- B Taverna
- CAPE-Lab (Computer-Aided Process Engineering Laboratory), Department of Industrial Engineering, University of Padua, Italy
| | - A Casonato
- Department of Medicine, University of Padua Medical School, Italy
| | - F Bezzo
- CAPE-Lab (Computer-Aided Process Engineering Laboratory), Department of Industrial Engineering, University of Padua, Italy
| | - F Galvanin
- Department of Chemical Engineering, University College London, United Kingdom.
| |
Collapse
|
7
|
Daidone V, Galletta E, De Marco L, Casonato A. Cryptic non-canonical splice site activation is part of the mechanism that abolishes multimer organization in the c.2269_2270del von Willebrand factor. Haematologica 2019; 105:1120-1128. [PMID: 31320553 PMCID: PMC7109749 DOI: 10.3324/haematol.2019.222679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 07/10/2019] [Indexed: 12/20/2022] Open
Abstract
We report a new pathogenic mechanism in von Willebrand disease involving the use of a non-canonical splicing site. The proband, carrying the homozygous c.2269_2270del mutation previously classified as a type 3 mutation, showed severely reduced plasma and platelet von Willebrand factor antigen levels and functions, and no factor VIII binding capacity. A particular von Willebrand factor multimer pattern emerged in plasma, characterized by the presence of only two oligomers: the dimer and an unusually large band, with no intermediate components. There were von Willebrand factor multimers in platelets, but each band ran more slowly than the normal counterpart. No anti-von Willebrand factor antibodies were detectable. The proband was classified as having severe type 1 von Willebrand disease. Seeking the relationship between phenotype and genotype, we found the c.2269_2270del mutation associated with three different RNA: r.2269_2270del (RNAI), giving a truncated von Willebrand factor protein; r.[2269_2270del;2282_2288del] (RNAII), resulting from activation of a cryptic “AG” splicing site; and r.[2269_2270del;2281_2282insAG] (RNAIII), where the wild-type “AG” acceptor of exon 18 was retained due to the non-canonical 2279-2280 “CG” acceptor splicing site being used. The aberrant RNAII and RNAIII caused the alteration of the furin cleavage and binding sites, respectively, both resulting in a von Willebrand factor protein characterized by the persistence of von Willebrand factor propeptide, as confirmed by western blot analysis of the recombinant mutated von Willebrand factor molecules produced in vitro. Taken together, these findings explain the residual von Willebrand factor synthesis, slower-running multimers, and absent factor VIII binding capacity. The apparently pure gene null mutation c.2269_2270del profoundly alters von Willebrand factor gene splicing, inducing a complex RNA expression pattern.
Collapse
Affiliation(s)
- Viviana Daidone
- University of Padua Medical School, Depar tment of Medicine, First Chair of Internal Medicine, Padua
| | - Eva Galletta
- University of Padua Medical School, Depar tment of Medicine, First Chair of Internal Medicine, Padua
| | - Luigi De Marco
- IRCCS, C.R.O. Aviano, Depar tment of Translational Research, Stem Cells Unit, Aviano, Italy
| | - Alessandra Casonato
- University of Padua Medical School, Depar tment of Medicine, First Chair of Internal Medicine, Padua
| |
Collapse
|
8
|
Casonato A, Galletta E, Daidone V. The elusive and heterogeneous pattern of type 2M von Willebrand disease: A diagnostic challenge. Eur J Haematol 2018; 101:684-690. [PMID: 30084138 DOI: 10.1111/ejh.13159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 07/24/2018] [Accepted: 07/25/2018] [Indexed: 06/08/2023]
Abstract
Type 2M is a very heterogeneous form of von Willebrand disease (VWD) associated with impaired platelet and von Willebrand factor (VWF) interactions not due to a lack of large VWF multimers. OBJECTIVES To investigate type 2M heterogeneity and to establish the most appropriate diagnostic flowchart. METHODS Hemostatic and genetic VWF analyses were performed in 14 type 2M VWD patients carrying the p.G1324S, p.R1374H, p.R1374C, p.A1344_A1350del, or p.F1293L mutations. RESULTS PFA-100 was always significantly prolonged, and ristocetin-induced platelet aggregation (RIPA) and VWF ristocetin cofactor (VWF:RCo) greatly reduced or absent. Plasma VWF antigen (VWF:Ag) was reduced except in the p.G1324S patient, while platelet VWF:Ag was normal or near normal except in the p.R1374C patients. The ratio of collagen binding (VWF:CB) to VWF:Ag was normal or near normal except in patients carrying the p.R1374H and p.A1344_A1350del mutations, whose large VWF multimers were slightly reduced. Multimer patterns were normal or lacking in large oligomers, or with larger than normal VWF components. CONCLUSIONS Only PFA100, RIPA and VWF:RCo were always abnormal. We thus propose a minimal diagnostic test battery: RIPA (demonstrating the defective VWF-platelet interaction), VWF:Ag (exploring VWF synthesis), and VWF:CB and its ratio (to explore multimer patterns). Other tests would only serve for confirmation, if necessary.
Collapse
Affiliation(s)
- Alessandra Casonato
- Department of Medicine, First Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
| | - Eva Galletta
- Department of Medicine, First Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
| | - Viviana Daidone
- Department of Medicine, First Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
| |
Collapse
|
9
|
Casonato A, Teresa Sartori M, de Marco L, Girolami A. 1-Desamino-8-D-Arginine Vasopressin (DDAVP) Infusion in Type IIB von Willebrand’s Disease: Shortening of Bleeding Time and Induction of a Variable Pseudothrombocytopenia. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647265] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have investigated the effects of 1-desamino-8-D-arginine vasopressin (DDAVP) infusion on platelet count and bleeding time in 4 patients with type IIB von Willebrand’s disease (vWd). Three of four patients showed a normalization of the bleeding time within 1 h after the infusion, while bleeding time was not modified in the fourth. In accordance with the literature, thrombocytopenia was observed after DDAVP infusion, but this thrombocytopenia was due to the anticoagulants used for blood collection. In two patients (F. I., G. F.) no thrombocytopenia was observed when platelets were counted by fingerstick method but there was a 20% platelet decrease in blood samples collected in sodium citrate and a 50% decrease in samples collected in EDTA. Dramatic falls in platelet counts (70–95%) were observed in the additional two patients (C. A., D.Z.) after DDAVP infusion, when both sodium citrate or EDTA were used as anticoagulants. In the latter two patients there was also a 50% decrease in platelet count when the fingerstick method was used. The decrease in the patient’s platelet count in EDTA samples after DDAVP infusion could be prevented, in part, by the previous additions of an anti GPIb monoclonal antibody and an anti GPIIb-IIIa monoclonal antibody.Thus, the thrombocytopenia observed in the four IIB vWd patients studied after DDAVP infusion seems to be, at least partially, a pseudothrombocytopenia depending on the calcium concentration in the blood samples and the availability of GPIb and GPIIb-IIIa receptors. These findings and the normalization of the bleeding time observed in three of the four patients has led us to reconsider the possible use of DDAVP in the treatment of our IIB vWd patients.
Collapse
Affiliation(s)
- Alessandra Casonato
- The University of Padua Medical School, Institute of Medical Semeiotics and Second Chair of Medicine, Padua, Italy
| | - M Teresa Sartori
- The University of Padua Medical School, Institute of Medical Semeiotics and Second Chair of Medicine, Padua, Italy
| | - Luigi de Marco
- The Centro di Riferimento Oncologico, USL 11, Aviano Pordenone, Italy
| | - Antonio Girolami
- The University of Padua Medical School, Institute of Medical Semeiotics and Second Chair of Medicine, Padua, Italy
| |
Collapse
|
10
|
Fabris F, Randi M, Casonato A, Luzzato G, Mazzucato M, Girolami A. The Significance of Plasma and/or Platelet Activated Products After Apheresis Procedures. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1665268] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- F Fabris
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - M Randi
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - A Casonato
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - G Luzzato
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - M Mazzucato
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - A Girolami
- Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| |
Collapse
|
11
|
Affiliation(s)
- Giuseppe Cella
- University of Padua, Medical School Istituto di Semeiotica Medica Padua, Italy
| | - Alessandra Casonato
- University of Padua, Medical School Istituto di Semeiotica Medica Padua, Italy
| | - Laura Visintin
- University of Padua, Medical School Istituto di Semeiotica Medica Padua, Italy
| | - Antonio Girolami
- University of Padua, Medical School Istituto di Semeiotica Medica Padua, Italy
| |
Collapse
|
12
|
Fabris F, Randi M, Casonato A, Scattolo N, Girolami A. Platelet Serotonin and Platelet Aggregation in the Differential Diagnosis of Thrombocytosis. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- F Fabris
- Institute of Medical Semeiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - M Randi
- Institute of Medical Semeiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - A Casonato
- Institute of Medical Semeiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - N Scattolo
- Institute of Medical Semeiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| | - A Girolami
- Institute of Medical Semeiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy
| |
Collapse
|
13
|
Francesconi M, Casonato A, Pagan S, Donella-Deana A, Pontara E, Girolami A, Deana R. Inhibitory Effect of Prostacyclin and Nitroprusside on Type IIB von Willebrand Factor-promoted Platelet Activation. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650601] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryVon Willebrand disease (vWD) of type IIB is a hereditary haemorragic disorder characterised by an excessive interaction of von Willebrand factor (vWF) with the platelet receptor GPIb which promotes platelet activation and aggregation through a phospholipase A2-mediated release of arachidonic acid.The present report shows that prostacyclin and nitroprusside, vaso-dilator-compounds that enhance the cAMP and cGMP concentration respectively, cause a drastic inhibition of the type IIB vWF-induced platelet responses including increase of cytosolic Ca2+ concentration, phosphorylation of pleckstrin (47 kDa) and myosin light chain (20 kDa), secretion of ATP and serotonin, and aggregation parallel to a decrease of arachidonic acid release. Type IIB vWF also elicits tyrosine phosphorylation of proteins with apparent molecular mass of 60,74,82 and 130 kDa. Prostacyclin, which induces per se tyrosine-phosphoryla-tion of proteins of about 38 and 45 kDa, inhibits drastically the type IIB vWF-promoted tyrosine-phosphorylation of the 74 kDa protein while inhibits slightly that of 60 kDa band. The protein tyrosine-kinase inhibitor genistein causes a little decrease in the type IIB vWF-induced release of arachidonic acid.It is concluded that the inhibition exerted by prostacyclin and nitroprusside on type IIB vWF-elicited platelet activation seems to be largely ascribable to prevention of the phospholipase A2 activation with the ensuing decrease of the subsequent protein tyrosine phosphorylation
Collapse
Affiliation(s)
- Mariangela Francesconi
- The Department of Biological Chemistry and Unit for the Study of Biomembranes of C.N.R, Italy
| | - Alessandra Casonato
- The institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padova, Italy
| | - Stefano Pagan
- The Department of Biological Chemistry and Unit for the Study of Biomembranes of C.N.R, Italy
| | - Arianna Donella-Deana
- The Department of Biological Chemistry and Unit for the Study of Biomembranes of C.N.R, Italy
| | - Elena Pontara
- The institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padova, Italy
| | - Antonio Girolami
- The institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padova, Italy
| | - Renzo Deana
- The Department of Biological Chemistry and Unit for the Study of Biomembranes of C.N.R, Italy
| |
Collapse
|
14
|
Francesconi MA, Deana R, Girolami A, Pontara E, Casonato A. Platelet Aggregation Induced by Plasma from Type IIB von Willebrand’s Disease Patients Is Associated with an Increase in Cytosolic Ca2+ Concentration. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649652] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe effect of type IIB von Willebrand’s factor (vWF) on platelet cytosolic Ca2+ ion concentration, measured by means of the probe fura 2, was investigated. Seven patients with type IIB von Willebrand disease (vWD) were studied. Addition of type IIB vWD plasma to platelet suspensions induced a cytosolic calcium increase accompanied by platelet aggregation. Both processes were completely abolished by addition of the calciumchelating agent EGTA, indomethacin, peptide RGDS, and monoclonal antibodies blocking the vWF binding site on GPIb-IX (LJIB1) or the cytoadhesive receptor on GPIIb-IIIa (LJCP8). The ADP-scavenger apyrase and the protein kinase C-inhibitor staurosporine partially inhibited the rate of the cytosolic calcium increase. No direct correlation between the extent of Ca2+ rise and the phenotypic expression of IIB vWD, such as the degree of spontaneous platelet aggregation or thrombocytopenia was apparent. It is suggested that aggregation and cytosolic Ca2+ increase in platelets exposed to plasma from type IIB vWD patients is mediated by a self-potentiating mechanism involving both GPIb and GPIIb-IIIa receptors as well as the thromboxane biosynthetic pathway.
Collapse
Affiliation(s)
| | - Renzo Deana
- The Department of Biological Chemistry, University of Padua, Italy
| | - Antonio Girolami
- Institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padua, Italy
| | - Elena Pontara
- Institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padua, Italy
| | - Alessandra Casonato
- Institute of Medical Semeiotics and Fourth Chair of Internal Medicine, University of Padua, Italy
| |
Collapse
|
15
|
Affiliation(s)
- M L Randi
- Institute of “Semeiotica Medica”, University of Padua Medical School, Padua, Italy
| | - F Fabris
- Institute of “Semeiotica Medica”, University of Padua Medical School, Padua, Italy
| | - A Casonato
- Institute of “Semeiotica Medica”, University of Padua Medical School, Padua, Italy
| | - A Girolami
- Institute of “Semeiotica Medica”, University of Padua Medical School, Padua, Italy
| |
Collapse
|
16
|
Ferrari M, Galvanin F, Barolo M, Daidone V, Padrini R, Bezzo F, Casonato A. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease. Thromb Haemost 2018; 118:309-319. [PMID: 29378356 DOI: 10.1160/th17-05-0375] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A reduced von Willebrand factor (VWF) synthesis or survival, or its increased proteolysis, alone or in combination, contributes to the development of von Willebrand disease (VWD).We describe a new, simple mechanistic model for exploring how VWF behaves in well-defined forms of VWD after its 1-desamino-8-D-arginine vasopressin (DDAVP)-induced release from endothelial cells. We aimed to ascertain whether the model can consistently predict VWF kinetic changes. The study involved 9 patients with VWD types Vicenza (a paradigmatic form with a reduced VWF survival), 8 type 2B, 2 type 2A-I, 1 type 2A-II (associated with an increased VWF proteolysis), and 42 normal controls, whose VWF levels were measured after a 24-hour-long DDAVP test. The rate constants considered were: k0, associated with the VWF release phase; k1, illustrating the phase of conversion from high- to low-molecular-weight VWF multimers; and ke, associated with the VWF elimination phase. The amount of VWF released (D) was also measured. ke and D were significantly higher in O than in non-O blood group controls; k1 was also higher, but less markedly so. All the parameters were accelerated in type Vicenza, especially ke (p < 0.0001), which explains the significant reduction in VWF half-life. In types 2B and 2A-II, k1 was one order of magnitude higher than in controls, which explains their loss of large VWF multimers. All parameters except ke were lower in type 2A-I.The proposed mechanistic model clearly describes the altered biochemical pathways in well-characterized VWD, prompting us to suggest that it might help clarify elusive forms of VWD too.
Collapse
Affiliation(s)
- Myriam Ferrari
- CAPE-Lab (Computer-Aided Process Engineering), Department of Industrial Engineering, University of Padua, Padua, Italy
| | - Federico Galvanin
- Department of Chemical Engineering, University College London, London, United Kingdom
| | - Massimiliano Barolo
- CAPE-Lab (Computer-Aided Process Engineering), Department of Industrial Engineering, University of Padua, Padua, Italy
| | - Viviana Daidone
- Department of Medicine, University of Padua Medical School, Padua, Italy
| | - Roberto Padrini
- Department of Medicine, University of Padua Medical School, Padua, Italy
| | - Fabrizio Bezzo
- CAPE-Lab (Computer-Aided Process Engineering), Department of Industrial Engineering, University of Padua, Padua, Italy
| | | |
Collapse
|
17
|
Daidone V, Galletta E, Casonato A. Type 1 von Willebrand disease due to a vicinal cysteine loss (p.C524Y) disclosed after a thrombotic episode. Thromb Res 2017; 161:91-93. [PMID: 29220693 DOI: 10.1016/j.thromres.2017.11.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 11/15/2017] [Accepted: 11/24/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Viviana Daidone
- University of Padua, Department of Medicine, Thrombohemorrhagic Disorders Unit, Padua, Italy
| | - Eva Galletta
- University of Padua, Department of Medicine, Thrombohemorrhagic Disorders Unit, Padua, Italy
| | - Alessandra Casonato
- University of Padua, Department of Medicine, Thrombohemorrhagic Disorders Unit, Padua, Italy.
| |
Collapse
|
18
|
Pontara E, Bertomoro A, Sartorello F, Girolami A, Casonato A. Which Assay Is the Most Suitable to Investigate von Willebrand Factor Functional Activity ? Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614616] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, Girolami A, Casonato A. Post-DDAVP Thrombocytopenia in Type 2B von Willebrand Disease Is not Associated with Platelet Consumption: Failure to Demonstrate Glycocalicin Increase or Platelet Activation. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614447] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThrombocytopenia is frequently reported in type 2B von Willebrand disease (vWD), and thought to be related to the abnormally high affinity of 2B von Willebrand factor (vWF) for platelet GPIb-IX. To gain an insight into the nature of this thrombocytopenia, we measured plasma glycocalicin (GC) levels (as a marker of platelet turnover), and platelet surface expression of the alpha granule protein P-selectin (as a marker of platelet activation) in 9 patients with type 2B vWD before, and in 4 patients also following the infusion of 1-desamino-8-d-arginine vasopressin (DDAVP). Three patients presented a persistent decrease of platelet counts in the resting condition. GC levels were within the normal range, regardless of the platelet counts, in all but one patient who presented, on the other hand, a normal platelet count. Moreover, platelets expressed normal amounts of P-selectin on their surface, regardless of platelet counts. These findings suggest that the thrombocytopenia observed in type 2B vWD is not due to platelet activation and subsequent consumption in circulation.Despite a significant, albeit transient, decrease in platelet count, DDAVP did not induce an increase in plasma GC levels, nor enhance P-selectin expression. These observations indicate that the acute post-DDAVP thrombocytopenia in type 2B vWD is not related to platelet activation and consumption. We advance that the post-DDAVP 2B vWF is hemostatically more active, and able to induce agglutination but not aggregation of circulating platelets. This would explain both the prompt recovery of basal platelet counts after the post-DDAVP decrease, and the lack of reported thrombotic complications in this disorder.Therefore, even though 2B vWF is characterized by an enhanced affinity for the platelet surface, its binding to platelet GPIb-IX in the soluble phase is not able to induce true platelet aggregation; vWF thus appears to be mainly an adhesive protein, rather than an aggregating agent.
Collapse
|
20
|
Saggiorato G, Pellati D, Casonato A, Spiezia L, Pontara E, Gavasso S, Girolami A, Sartori M. Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1613603] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummarySevere type I plasminogen deficiency is the underlying cause of ligneous conjunctivitis, a rare disease characterized by wood-like pseudomembranes developing on the ocular and extraocular mucosa. Two unrelated female patients with ligneous conjunctivitis and moderate hypoplasminogenemia are described. Being of fertile age, they were treated with oral contraceptives, which determined a marked increase in plasminogen levels. Moreover, a palpebral pseudomembrane stopped growing in one patient and disappeared completely in the other while on the estroprogestinic treatment. In patient n.2,who also suffered from von Willebrand’s disease, prior Cushing’s disease induced an increase in both von Willebrand factor and plasminogen levels, which dropped after curative hypophysectomy. Genetic plasminogen study showed a 19Lys>Glu mutation in a heterozygous state in the first proposita and in a homozygous state in the second proband. In addition, both index patients were homozygous for a new intron F-14T>G mutation, which was found to reduce the acceptor splicing site prediction score.In conclusion, oral contraceptive therapy may improve plasminogen deficiency and deserves attention as an alternative therapeutic approach in selected cases of ligneous conjunctivitis with low, but not absent, plasminogen synthesis.
Collapse
|
21
|
Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Cattini MG, Daidone V, Szukowska M, Pagnan A, Casonato A. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: An elusive phenotype and a difficult diagnosis. Thromb Haemost 2017; 98:1182-7. [DOI: 10.1160/th07-05-0347] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryMutations in the A1 domain of von Willebrand factor (VWF) may be associated with gain of function in theVWF-platelet GPIb interaction and consumption of largeVWF multimers, as seen in type 2B von Willebrand disease (VWD). We report a new VWF abnormality associated with greater VWF-GPIb interaction in the presence of all VWF multimers. The index case is a woman with a lifelong history of bleeding, found hyperresponsive to ristocetin with spontaneous platelet aggregation (SPA). She had normal factor VIII,VWF:Ag,VWF:RCo and VWF:CB levels, normal VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag ratios, and a full panel of plasma and platelet VWF multimers. A missense mutation (4115T>G) was found in exon 28 of theVWF gene, which replaced a isoleucine with a serine at position 1372 of pre-pro-VWF (I1372S) at heterozygous level. Recombinant VWF carrying the I1372S mutation and showing a normal VWF multimer organisation was capable of inducing SPA on normal plateletrich plasma (unlike wild-type VWF), as well as a hyper-response to ristocetin in the same platelets (0.6 mg/ml ristocetin vs. 1.2 of wild-type VWF). The new I1372S VWF mutation, characterised by SPA and hyper-responsiveness to ristocetin thus has some of the features of type 2B VWD, but not the lack of large VWF multimers, so we defined this variant as type 2B-likeVWD. Why I1372SVWF is associated with bleeding symptoms, despite normalVWF levels and multimer organisation,remains to be seen.
Collapse
|
22
|
Gallinaro L, Sartorello F, Pontara E, Cattini M, Bertomoro A, Bartoloni L, Pagnan A, Casonato A. Combined partial exon skipping and cryptic splice site activation as a new molecular mechanism for recessive type 1 von Willebrand disease. Thromb Haemost 2017. [DOI: 10.1160/th06-07-0417] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryWe describe the complex picture associated with a mutated splice junction in intron 13 of von Willebrand factor (VWF) gene. The proband, characterized by a marked decrease in plasma and platelet VWF and near normal multimer organization, was classified as recessive type 1 von Willebrand disease (VWD). Genetic analysis demonstrated that he was homozygous for the 1534–3C>A mutation in the consensus sequence of the acceptor splicing site of intron 13 of the VWF gene. Platelet mRNA analysis documented three VWF transcripts: a wild type generated by the correct recognition of the mutated splice site, a smaller transcript not containing exon 14, and a longer one that, in addition to exons 13 and 14, included a 62bp fragment corresponding to the end of intron 13. The small transcript derives from the skipping of exon 14, the long one from the activation of a cryptic splice site in intron 13; both show a premature stop codon inVWF propeptide, so the probandVWF derives entirely from the correct splice site recognition. Combined incomplete exon skipping and cryptic splice site activation are first recognized in VWD. Since the 1534–3C>A mutation does not abolish the normal processing of mRNA, it is unlikely to be found in type 3VWD. This mutation therefore appears to be peculiar to type 1 VWD.
Collapse
|
23
|
Marco L, Gallinaro L, Sztukowska M, Mazzuccato M, Battiston M, Pagnan A, Ruggeri Z, Casonato A. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Thromb Haemost 2017. [DOI: 10.1160/th06-11-0647] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryThe normal von Willebrand factor (vWF) multimer pattern results from the ADAMTS-13 cleavage of the Tyr1605-Met1606 bond in the A2 domain of vWF. We identified a patient with severe von Willebrand disease (vWD) homozygously carrying a Cys to Phe mutation in position 2362 of vWF with markedly altered vWF multimers and an abnormal proteolytic pattern. The proband’s phenotype was characterized by a marked drop in plasma vWF antigen and ristocetin cofactor activity, and a less pronounced decrease in FVIII. The vWF multimers lacked any triplet structure, replaced by single bands with an atypical mobility, surrounded by a smear, and abnormally large vWF multimers. Analysis of the plasma vWF subunit's composition revealed the 225 kDa mature form and a single 205 kDa fragment, but not the 176 kDa and 140 kDa fragments resulting from cleavage by ADAMTS-13.The 205 kDa fragment was distinctly visible, along with the normal vWF cleavage products, in the patient's parents who were heterozygous for the Cys2362Phe mutation. Their vWF levels were mildly decreased and vWF multimers were organized in triplets, but also demonstrated abnormally large forms and smearing. Our findings indicate that a proper conformation of the B2 domain, which depends on critical Cys residues, may be required for the normal proteolytic processing of vWF multimers.
Collapse
|
24
|
Sponga S, Pontara E, Cattini MG, Basso C, Thiene G, Cella G, Daidone V, Gerosa G, Pagnan A, Casonato A. von Willebrand factor abnormalities in aortic valve stenosis: Pathophysiology and impact on bleeding. Thromb Haemost 2017; 106:58-66. [DOI: 10.1160/th10-10-0634] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Accepted: 03/14/2011] [Indexed: 11/05/2022]
Abstract
SummaryAcquired von Willebrand syndrome (AVWS) may complicate severe aortic valve stenosis, due to a reduction in the haemostatically more efficient large von Willebrand factor (VWF) multimers. This study was designed to analyse the relevance of VWF abnormalities and haemorrhagic diathesis in severe aortic valve stenosis. Forty-one consecutive patients undergoing valve replacement were investigated: seven had minor bleeding symptoms in their recent history; 10 (24.3%) had a reduced VWF collagen binding (VWF:CB) to VWF antigen ratio, and 33 (80.5%) had a decrease in large VWF multimers. The shortage of large multimers was not associated with any accumulation of small VWF multimers (apparently ruling out any increased VWF proteolysis), nor was there any increase in VWF propeptide, which excludes a shorter VWF survival. The risk of developing VWF abnormalities was higher in patients with rheumatic valve disease than in degenerative cases (p=0.025) and in valves with <50% of residual endothelial cells (p=0.004). Bleeders differed from non-bleeders in that they had a higher mean transvalvular gradient and a more marked decrease in large VWF multimers. VWF abnormalities did not exacerbate peri-operative blood loss, however – a finding consistent with the full correction of these VWF abnormalities, seen already on the first postoperative day and persisting for up to six months after surgery. According to the data obtained in our cohort of patients VWF abnormalities are common in severe aortic stenosis, particularly in cases of rheumatic valve disease, but loss of the largest multimers does not seem to cause clinical bleeding in most patients.
Collapse
|
25
|
Daidone V, Cattini MG, Pontara E, Sartorello F, Gallinaro L, Marotti A, Scaroni C, Pagnan A, Casonato A. Microsatellite (GT)n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. Thromb Haemost 2017. [DOI: 10.1160/th08-08-0501] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryVon Willebrand factor (VWF) levels vary considerably in normal individuals, influenced by inherited and acquired modulators. ABO blood group is the major inherited determinant of VWF levels, but a role has also been attributed to the VWF gene promoter, haplotype 1 (-3268G/-2709C/-2661A/-2527G) being associated with higher VWF levels than haplotype 2 (-3268C/-2709T/-2661G/-2527A), and the polymorphic locus (GT)n modulating the shear stress-induced activation of the VWF promoter. We characterized the (GT)n of the VWF promoter in 394 healthy individuals and assessed whether its variable length influenced VWF levels in normal conditions. (GT)n proved highly polymorphic, with alleles from 15 to 24 repeats long. (GT)21 and (GT)19 were the most common variants (37.4% and 34.4%, respectively). Short GT repeats (15–19) segregated mainly with haplotype 1, long GT repeats (20–24) with haplotype 2 (p<0.0001). The number of GT repeats did not correlate with VWF levels, nor did such levels correlate with haplotypes 1 and 2, considered alone or in association with the (GT)n locus. We conclude that (GT)n and -3268/-2709/-2661/-2527 loci are in strong linkage disequilibrium. This polymorphic region of the VWF promoter does not affect VWF levels under normal conditions, though it might represent an environmentally activable VWF regulation site.
Collapse
|
26
|
Casonato A, Galletta E, Sarolo L, Daidone V. Type 2N von Willebrand disease: Characterization and diagnostic difficulties. Haemophilia 2017; 24:134-140. [PMID: 29115006 DOI: 10.1111/hae.13366] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/02/2017] [Indexed: 11/30/2022]
Abstract
INTRODUCTION An abnormal factor VIII (FVIII) binding capacity of von Willebrand factor (VWF) identifies type 2N von Willebrand disease (VWD). Type 2N VWD patients are identified by means of the VWF FVIII binding (VWF:FVIIIB) assay, and especially their VWF:FVIIIB/VWF:Ag ratio (VWF:FVIIIB ratio). AIM We report on our 15-year experience of diagnosing type 2N VWD. METHODS We have performed 2178 VWF:FVIIIB assays in bleeders and normal subjects. RESULTS von Willebrand factor (VWF):FVIIIB was reduced in 682, but only 60 had low VWF:FVIIIB ratios (<0.74). Among nine patients who had a VWF:FVIIIB ratio below 0.3, four had normal VWF levels and were homozygotes for the p.R854Q mutation; the other five had low VWF levels due to a quantitative VWF mutation combined with p.R854Q. The VWF:FVIIIB ratio ranged between 0.3 and 0.73 in 51 subjects; 34 of them were heterozygotes for the p.R854Q mutation, while one carried the p.R760C. The heterozygotes for type 2N included subjects with or without bleeding symptoms, the former with significantly lower mean VWF levels than the latter. Among the 116 normal subjects tested, six were heterozygotes for the p.R854Q mutation (all asymptomatic). CONCLUSIONS The prevalence of type 2N in our VWD cohort was 2.5%, and 5.2% of the general population in Northeast Italy was found heterozygous for the p.R854Q mutation. It might be difficult to reveal a type 2N defect using routine tests alone, especially when it is combined with a quantitative VWF mutation. Accordingly, we always recommend VWF:FVIIIB assay in the diagnostic workup of VWD.
Collapse
Affiliation(s)
- A Casonato
- Department of Medicine, Hemorrhagic and Thrombotic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - E Galletta
- Department of Medicine, Hemorrhagic and Thrombotic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - L Sarolo
- Department of Medicine, Hemorrhagic and Thrombotic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - V Daidone
- Department of Medicine, Hemorrhagic and Thrombotic Disorders Unit, University of Padua Medical School, Padua, Italy
| |
Collapse
|
27
|
Castaldello C, Galvanin F, Casonato A, Padrini R, Barolo M, Bezzo F. A model-based protocol for the diagnosis of von Willebrand disease. CAN J CHEM ENG 2017. [DOI: 10.1002/cjce.22964] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Christopher Castaldello
- CAPE-Lab -Computer-Aided Process Engineering Laboratory, Department of Industrial Engineering; University of Padova; via Marzolo 9, 35131 Padova Italy
| | - Federico Galvanin
- Department of Chemical Engineering; University College London; Torrington Place, London WC1E 7JE United Kingdom
| | - Alessandra Casonato
- Department of Medicine; University of Padua Medical School; Via Ospedale Civile 105, 35128 Padova Italy
| | - Roberto Padrini
- Department of Medicine; University of Padua Medical School; Via Ospedale Civile 105, 35128 Padova Italy
| | - Massimiliano Barolo
- CAPE-Lab -Computer-Aided Process Engineering Laboratory, Department of Industrial Engineering; University of Padova; via Marzolo 9, 35131 Padova Italy
| | - Fabrizio Bezzo
- CAPE-Lab -Computer-Aided Process Engineering Laboratory, Department of Industrial Engineering; University of Padova; via Marzolo 9, 35131 Padova Italy
| |
Collapse
|
28
|
Abstract
Most, but not all patients with type 2B von Willebrand disease (VWD)—which features gain-of-function mutations in the A1 domain of von Willebrand factor (VWF)—have no circulating large VWF multimers. Similarities and differences were analysed in 33 type 2B patients, 12 with a normal and 21 with an abnormal multimer pattern, to see whether they should be considered separately. The minimum aggregating dose of ristocetin was similarly reduced in both patient groups, and modulated by their underlying VWF mutations. Platelet VWF content was normal in all patients lacking in large multimers, but sometimes reduced in those with a normal multimer pattern. All the former patients and none of the latter had persistent or transient thrombocytopenia. A short VWF half-life (affecting plasma VWF levels) was seen in both groups, but more pronounced in patients without large multimers. Bleeding scores were also high in all patients, but more so in those without large multimers, apparently regardless of their platelet count. The marked phenotypic heterogeneity of type 2B VWD concerns not only patients’ VWF multimer pattern, but also their bleeding risk, and consequently their appropriate treatment too. Hence the need to clearly distinguish between type 2B VWD with normal or abnormal VWF multimers.
Collapse
Affiliation(s)
- Alessandra Casonato
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
- * E-mail:
| | - Viviana Daidone
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Eva Galletta
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | | |
Collapse
|
29
|
Bilora F, Zanon E, Casonato A, Bertomoro A, Petrobelli F, Cavraro M, Campagnolo E, Girolami A. Type IIB von Willebrand Disease: Role of Qualitative Defects in Atherosclerosis and Endothelial Dysfunction. Clin Appl Thromb Hemost 2016; 13:384-90. [PMID: 17911189 DOI: 10.1177/1076029607303613] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Objective. To verify whether a hereditary bleeding tendency, such as von Willebrand disease (vWD) type IIB, protects against the onset of atherosclerosis. Participants and Methods. Twenty-four patients with vWD type IIB and 24 healthy controls, matched for common atherosclerotic risk factors. All patients were evaluated by color Doppler ultrasound of the common carotid, carotid bifurcation, common femoral artery, brachial artery, and abdominal aorta, investigating intima-media thickness (IMT) and presence of plaques in each arterial district. Flow mediated dilation (FMD) of the brachial artery was used to test endothelial function. Results. vWD type IIB patients presented no significant difference in IMT in any arterial district. FMD showed no differences between the 2 groups. Conclusions. The quantitative clotting defect characteristic of vWD type IIB does not seem to protect against atherosclerosis.
Collapse
Affiliation(s)
- Franca Bilora
- Clinica Medica II, Università di Padova, Padova, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Patrassi GM, Sartori MT, Rigotti P, Di Landro D, Perin A, Theodoridis P, Saggiorato G, Casonato A, Girolami A. Coagulation and Fibrinolysis During the First Year of Immunosuppressive Treatment in Renal Transplantation: Correspondence Between Hypercoagulable State and Steroid Therapy. Clin Appl Thromb Hemost 2016. [DOI: 10.1177/107602969500100406] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
An increased incidence of thromboembolic complications has been reported after kidney transplantation, and hypercoagulability has been associated with immunosuppressive treatment, specifically with Cyclosporin A. Hypercorticism due to prolonged steroid therapy or to Cushing's disease has been associated with a similar hypercoagulable state and thrombotic risk. The aims of this study were first to evaluate coagulation and fibrinolytic behavior in 27 patients at different times during the first year after renal transplantation and then to compare the same patients' coagulation and fibrinolytic findings 1 month after transplantation with those of a normal control group and a group of Cushing's patients. Compared with normal controls, renal transplant patients and Cushing's patients showed a similar hypercoagulable and hypofibrinolytic state, with a significant shortening in activated partial thromboplastin time and increase in factor VIII-von Willebrand factor complex, tissue plasminogen activator concentration, and plasminogen activator inhibitor activity and concentration. Other test results in the two groups showed no differences. The same abnormalities were present in the renal transplant group for the entire period of study. Our results suggest that a hypercoagulable and hypofibrinolytic state persists almost 1 year after renal transplantation and that these abnormalities are very similar to those present in Cushing's disease. Steroid treatment seems to play a key role in determining thromboembolic risk after renal transplantation. Key Words: Renal transplantation-Hypercoagulable state—von Willebrand factor-Hypofibrinolysis-Plasminogen activator inhibitor-Steroid therapy-Cyclosporin A.
Collapse
Affiliation(s)
| | | | - Paolo Rigotti
- Institute of General Surgery , University of Padua Medical School, Padua, Italy
| | | | - Antonella Perin
- Institute of Medical Semiotics, IV Chair of Internal Medicine
| | | | | | | | | |
Collapse
|
31
|
Daidone V, Barbon G, Cattini MG, Pontara E, Romualdi C, Di Pasquale I, Hosokawa K, Casonato A. Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease. Haemophilia 2016; 22:949-956. [PMID: 27293213 DOI: 10.1111/hae.12971] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2016] [Indexed: 11/26/2022]
Abstract
INTRODUCTION The heterogeneity of von Willebrand disease (VWD) makes its diagnosis a difficult task. METHODS We report here on the usefulness of a microchip-based flow-chamber system, the total thrombus-formation analysis system (T-TAS), in the identification and characterization of VWD. Thirty VWD patients and 20 healthy subjects were studied with the T-TAS platelet (PL) and atherome (AR) microchips developed for the in vitro assessment of platelet thrombus formation and fibrin-rich platelet thrombus formation respectively. RESULTS Samples from severe type 1 VWD, characterized by von Willebrand factor (VWF) levels below 10 U dL-1 , failed to occlude either the PL or the AR chip capillaries, while the occlusion times were normal in patients with mild type 1 VWD (VWF above 25 U dL-1 ). PL and/or AR chip occlusion occurred, but took longer than normal, for samples from type Vicenza and type 1 VWD patients, whose VWF levels ranged between 10 and 25 U dL-1 . No PL or AR chip capillary occlusion was seen for samples from patients with type 2A or 2B VWD featuring the absence of large VWF multimers, whereas no abnormalities emerged for type 2B patients with normal multimer patterns. CONCLUSION The T-TAS appears to be sensitive mainly to plasma VWF concentration and the presence of large multimers. Failure of the PL and AR chips to become occluded points to a lack of large VWF multimers, or type 1 VWD with VWF levels below 10 U dL-1 . Although the T-TAS does not assure a precise VWD diagnosis, it does point us in the right direction, and thus seems a useful global preliminary test.
Collapse
Affiliation(s)
- V Daidone
- Department of Cardiologic, Thoracic and Vascular Sciences, Thrombohemorrhagic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - G Barbon
- Veneto Institute of Oncology IRCCS, Familial Cancer Clinic and Oncoendocrinology, Padua, Italy
| | - M G Cattini
- Department of Cardiologic, Thoracic and Vascular Sciences, Thrombohemorrhagic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - E Pontara
- Department of Cardiologic, Thoracic and Vascular Sciences, Thrombohemorrhagic Disorders Unit, University of Padua Medical School, Padua, Italy
| | - C Romualdi
- Department of Biology, University of Padua, Padua, Italy
| | - I Di Pasquale
- Department of Medicine, University of Padua, Padua, Italy
| | - K Hosokawa
- Research Institute Fujimori Kogyo Co., Yokohama, Japan
| | - A Casonato
- Department of Medicine, University of Padua, Padua, Italy
| |
Collapse
|
32
|
Zilio M, Mazzai L, Sartori MT, Barbot M, Ceccato F, Daidone V, Casonato A, Saggiorato G, Noventa F, Trementino L, Prandoni P, Boscaro M, Arnaldi G, Scaroni C. A venous thromboembolism risk assessment model for patients with Cushing's syndrome. Endocrine 2016; 52:322-32. [PMID: 26113424 DOI: 10.1007/s12020-015-0665-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 06/12/2015] [Indexed: 11/28/2022]
Abstract
Cushing's syndrome (CS) is associated with an incidence of venous thromboembolism (VTE) about ten times higher than in the normal population. The aim of our study was to develop a model for identifying CS patients at higher risk of VTE. We considered clinical, hormonal, and coagulation data from 176 active CS patients and used a forward stepwise logistic multivariate regression analysis to select the major independent risk factors for thrombosis. The risk of VTE was calculated as a 'CS-VTE score' from the sum of points of present risk factors. VTE developed in 20 patients (4 pulmonary embolism). The group of CS patients with VTE were older (p < 0.001) and had more cardiovascular events (p < 0.05), infections and reduced mobility (both p < 0.001), higher midnight plasma cortisol levels (p < 0.05), and shorter APTT (p < 0.01) than those without. We identified six major independent risk factors for VTE: age ≥69 years and reduced mobility were given two points each, whereas acute severe infections, previous cardiovascular events, midnight plasma cortisol level >3.15 times the normality and shortened APTT were given one point each. A CS-VTE score <2 anticipated no risk of VTE; a CS-VTE score of two mild risk (10 %); a CS-VTE score of three moderate risk (46 %); a CS-VTE score ≥4 high risk (85 %). Considering a score ≥3 as predictive of VTE, 94 % of the patients were correctly classified. A simple score helps stratify the VTE risk in CS patients and identify those who could benefit from thromboprophylaxis.
Collapse
Affiliation(s)
- Marialuisa Zilio
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy.
| | - Linda Mazzai
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy
| | - Maria Teresa Sartori
- Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University-Hospital of Padova, Padua, Italy
| | - Mattia Barbot
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy
| | - Filippo Ceccato
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy
| | - Viviana Daidone
- Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University-Hospital of Padova, Padua, Italy
| | - Alessandra Casonato
- Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University-Hospital of Padova, Padua, Italy
| | - Graziella Saggiorato
- Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University-Hospital of Padova, Padua, Italy
| | - Franco Noventa
- Clinical Medicine V, Department of Medicine DIMED, University-Hospital of Padova, Padua, Italy
| | - Laura Trementino
- Endocrinology Unit, Polytechnic University of Marche, Ancona, Italy
| | - Paolo Prandoni
- Clinical Medicine II, Department of Cardiac, Thoracic and Vascular Sciences, University-Hospital of Padova, Padua, Italy
| | - Marco Boscaro
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy
| | - Giorgio Arnaldi
- Endocrinology Unit, Polytechnic University of Marche, Ancona, Italy
| | - Carla Scaroni
- Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Via Ospedale, 105 35128, Padua, Italy
| |
Collapse
|
33
|
Casonato A, Pontara E, Morpurgo M, Sartorello F, De Groot PG, Cattini MG, Daidone V, De Marco L. Higher and lower active circulating VWF levels: different facets of von Willebrand disease. Br J Haematol 2015; 171:845-53. [DOI: 10.1111/bjh.13785] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 08/03/2015] [Indexed: 11/30/2022]
Affiliation(s)
| | - Elena Pontara
- Department of Cardiologic, Thoracic and Vascular Sciences; University of Padua; Padua Italy
| | - Margherita Morpurgo
- Pharmaceutical Chemistry and Pharmacology Department; University of Padua; Padua Italy
| | | | - Philip G. De Groot
- Department of Clinical Chemistry and Haematology; University Medical Centre Utrecht; Utrecht the Netherlands
| | - Maria G. Cattini
- Department of Cardiologic, Thoracic and Vascular Sciences; University of Padua; Padua Italy
| | - Viviana Daidone
- Department of Cardiologic, Thoracic and Vascular Sciences; University of Padua; Padua Italy
| | - Luigi De Marco
- Department of Translational Research; Stem Cells Unit; IRCCS; C.R.O.; Aviano Italy
- Department of Molecular Medicine; The Scripps Research Institute; La Jolla CA USA
| |
Collapse
|
34
|
Casonato A, Cattini MG, Barbon G, Daidone V, Pontara E. Severe, recessive type 1 is a discrete form of von Willebrand disease: the lesson learned from the c.1534-3C>A von Willebrand factor mutation. Thromb Res 2015; 136:682-6. [PMID: 26251079 DOI: 10.1016/j.thromres.2015.07.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 07/03/2015] [Accepted: 07/14/2015] [Indexed: 10/23/2022]
Abstract
UNLABELLED Type 1 von Willebrand disease (VWD) is transmitted mainly as a dominant trait - especially in forms involving von Willebrand factor (VWF) levels below 20 U/dL - and less frequently as a recessive trait. In the latter case, mutations at heterozygous level may be associated with type 3 carrier status, while mutations at homozygous or compound heterozygous level often coincide with type 3 VWD. Here we present a recessive, severe type 1 form as a distinct type of VWD. Eight patients with severe type 1 VWD belonging to 7 unrelated families were studied. They had VWF levels below 10 U/dL, FVIII higher than 10 U/dL, and a significantly lower than normal platelet VWF content. All patients were homozygous or compound heterozygous for the c.1534-3C>A VWF mutation, that simultaneously induces the skipping of exon 14, the activation of a cryptic splice site, and a normal VWF gene transcription. This means that one of the three different mRNA generated assures the synthesis of normal VWF. The probands' relatives who were heterozygous for the c.1534-3C>A mutation always had low platelet VWF levels, sometimes with circulating VWF levels within normal range. This finding confirms the utility of measuring platelet VWF content to identify an abnormal VWF synthesis. Because the c.1534-3C>A mutation impairs, but does not abolish normal mRNA processing, it may never cause type 3 VWD. We propose a model of severe recessive type 1 VWF defect associated with mutations that sporadically go undetected by the cells' molecular machinery, as the c.1534-3C>A VWF mutation. BULLET POINTS What is known about this topic? - Type 1 VWD is transmitted mainly as a dominant trait. - Recessive type 1 mutations at homozygous or compound heterozygous level are often associated with type 3 VWD, and at heterozygous level with type 3 VWD carrier status. What does this paper add? - There are quantitative VWF mutations, such as c.1534-3C>A, that impair, but do not abolish normal mRNA processing. - The c.1534-3C>A VWF mutation simultaneously induces the skipping of exon 14, the activation of a cryptic splice site, and a normal VWF gene transcription. - The c.1534-3C>A mutation is the archetype of mutations that cause severe recessive type 1 VWD, but never type 3 VWD. - Recessive, severe type 1 appears to be a distinct form of VWD.
Collapse
Affiliation(s)
- A Casonato
- University of Padua Medical School, Department of Medicine, Thrombohemorrhagic Disorders Unit, Padua, Italy.
| | - M G Cattini
- University of Padua Medical School, Department of Cardiologic, Thoracic and Vascular Sciences, Padua, Italy
| | - G Barbon
- University of Padua Medical School, Department of Cardiologic, Thoracic and Vascular Sciences, Padua, Italy
| | - V Daidone
- University of Padua Medical School, Department of Cardiologic, Thoracic and Vascular Sciences, Padua, Italy
| | - E Pontara
- University of Padua Medical School, Department of Cardiologic, Thoracic and Vascular Sciences, Padua, Italy
| |
Collapse
|
35
|
Daidone V, Saga G, Barbon G, Pontara E, Cattini MG, Morpurgo M, Zanotti G, Casonato A. The p.R1819_C1948delinsS mutation makes von Willebrand factor ADAMTS13-resistant and reduces its collagen-binding capacity. Br J Haematol 2015; 170:564-73. [PMID: 25904363 DOI: 10.1111/bjh.13472] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 02/23/2015] [Indexed: 12/21/2022]
Abstract
This report concerns abnormal ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) and collagen interactions coinciding with the p.R1819_C1948delinsS von Willebrand factor (VWF) mutation associated with the deletion of the C-terminus of the A3 domain (amino acids 1819-1947) in a patient with a history of bleeding. The von Willebrand disease (VWD) phenotype of the patient featured low plasma and platelet VWF, multimers with smears extending over the highest normal oligomers in plasma, but not platelets, and an impaired collagen-binding capacity. In vitro full-length p.R1819_C1948delinsS VWF expression showed impaired VWF release, increased cellular content with normally-multimerized VWF and impaired collagen binding. The recombinant p.R1819_C1948delinsS VWF fragment, extending from domains A2 to B3 (p.R1819_C1948delinsS A2-B3 VWF), was completely resistant to proteolysis by ADAMTS13 in the presence of 1·5 mol/l urea, unlike its normal counterpart. The defect stems from impaired ADAMTS13 binding to p.R1819_C1948delinsS A2-B3, analysed under static conditions. Partial deletion of the C-terminus of the A3 domain thus makes VWF resistant to ADAMTS13, interfering with ADAMTS13 binding to VWF, and impairing the collagen-binding capacity of VWF. The p.R1819_C1948delinsS mutation has both haemorrhagic features (defective collagen binding, reduced VWF levels) and prothrombotic (ADAMTS13 resistance) features, and the latter probably mitigate the patient's bleeding symptoms.
Collapse
Affiliation(s)
- Viviana Daidone
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Giorgia Saga
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Giovanni Barbon
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Elena Pontara
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Maria G Cattini
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| | - Margherita Morpurgo
- Pharmaceutical Chemistry and Pharmacology Department, University of Padua, Padua, Italy
| | - Giuseppe Zanotti
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Alessandra Casonato
- Thrombohaemorrhagic Disorders Unit, Department of Medicine, University of Padua, Padua, Italy
| |
Collapse
|
36
|
Daidone V, Barbon G, Pontara E, Cattini GM, Gallinaro L, Zampese E, Pizzo P, Casonato A. Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor. Thromb Haemost 2014; 112:1159-66. [PMID: 25230768 DOI: 10.1160/th14-04-0391] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Accepted: 07/22/2014] [Indexed: 11/05/2022]
Abstract
Cysteines play a key part in von Willebrand factor (VWF) dimerisation and polymerisation, and their loss may severely affect VWF structure and function. We report on three patients with type 3 von Willebrand disease carrying the new c.1751G>T missense mutation that induces the substitution of cysteine 584 by phenylalanine (C584F), and the deletion of seven nucleotides in exon 7 (c.729_735del), producing a premature stop codon at position 454 (E244Lfs*211). VWF was almost undetectable in the patients' plasma and platelets, while a single, poorly represented, oligomer emerged on plasma VWF multimer analysis. No post-DDAVP increase in VWF and factor VIII was observed. Expressing human recombinant C584F-VWF in HEK293T cells showed that C584F-VWF was synthesised and multimerised but not secreted - apart from the first oligomer, which was slightly represented in the conditioned medium, with a pattern similar to the patients' plasma VWF. The in vitro expression of the E244Lfs*211-VWF revealed a defective synthesis of the mutated VWF, with a behavior typical of loss of function mutations. Cellular trafficking, investigated in HEK293 cells, indicated a normal C584F-VWF content in the endoplasmic reticulum and Golgi apparatus, confirming the synthesis and multimerisation of C584F-VWF. No pseudo-Weibel Palade bodies were demonstrable, however, suggesting that C584F mutation impairs the storage of C584F-VWF. These findings point to cysteine 584 having a role in the release of VWF and its targeting to pseudo-Weibel Palade bodies in vitro, as well as in its storage and release by endothelial cells in vivo.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - A Casonato
- A. Casonato, Via Ospedale Civile 105, 35128 Padova, Italy, Tel.: +39 049 821 7177, Fax: +39 049 657391, E-mail:
| |
Collapse
|
37
|
Zilio M, Barbot M, Ceccato F, Camozzi V, Bilora F, Casonato A, Frigo AC, Albiger N, Daidone V, Mazzai L, Mantero F, Scaroni C. Diagnosis and complications of Cushing's disease: gender-related differences. Clin Endocrinol (Oxf) 2014; 80:403-10. [PMID: 23889360 DOI: 10.1111/cen.12299] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Revised: 05/10/2013] [Accepted: 07/22/2013] [Indexed: 12/30/2022]
Abstract
OBJECTIVE Cushing's disease (CD) presents a remarkable preponderance in female gender, with a female-to-male ratio of 3-8:1. The aim of this study was to evaluate gender-related differences in the presentation of CD, as regards: biochemical indices of hypercortisolism; sensitivity of diagnostic tests; clinical features and complications of disease. METHODS We retrospectively studied 84 adult patients with CD, 67 women and 17 men, evaluated at diagnosis. We compared the features of the disease between the sexes and analysed the effect of gender on CD complications, adjusted for potential confounders (age, gonadal status, BMI, urinary free cortisol values). RESULTS We observed no differences between males and females as regards age at diagnosis, disease duration and BMI. Men, compared with women, presented higher urinary free cortisol values (P < 0·001) and ACTH values (P < 0·05). As regards diagnostic tests, men presented a lower ACTH response to DDAVP stimulation (P < 0·05). The pituitary tumour itself was less easily visualized by pituitary MRI in males compared with females (P < 0·05). Furthermore, some complications of disease were more frequent or more severe in men, in particular hypokalaemia (P < 0·05), hypercoagulable state and osteoporosis at lumbar spine (P < 0·01), with consequent higher risk of vertebral fractures. Male gender was found to be an independent risk factor for dyslipidaemia, severity of hypertension, lumbar osteoporosis and fractures. CONCLUSIONS Although CD is less frequent in male patients, in this gender, it presents with more florid clinical manifestations and may imply more diagnostic difficulties.
Collapse
Affiliation(s)
- Marialuisa Zilio
- Endocrinology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Affiliation(s)
- Federico Galvanin
- CAPE-Lab - Computer-Aided Process Engineering Laboratory; Dept. of Industrial Engineering, University of Padova; 35131 Padova Italy
| | - Massimiliano Barolo
- CAPE-Lab - Computer-Aided Process Engineering Laboratory; Dept. of Industrial Engineering, University of Padova; 35131 Padova Italy
| | - Roberto Padrini
- Dept. of Medicine; University of Padova Medical School; 35128 Padova Italy
| | - Alessandra Casonato
- Dept. of Cardiologic, Thoracic and Vascular Sciences; University of Padova Medical School; 35128 Padova Italy
| | - Fabrizio Bezzo
- CAPE-Lab - Computer-Aided Process Engineering Laboratory; Dept. of Industrial Engineering, University of Padova; 35131 Padova Italy
| |
Collapse
|
39
|
Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand’s disease: A critical review of the literature. J Thromb Thrombolysis 2014; 21:175-8. [PMID: 16622614 DOI: 10.1007/s11239-006-5732-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
All patients with von Willebrand's disease (vWD) who showed an arterial or venous thrombosis and were reported in the literature have been evaluated. 11 patients had arterial thrombosis while 19 had venous thrombosis for a total of 30 cases. 9 out the 11 cases with arterial thrombosis had myocardial infarction. Two had cerebral thrombosis. Associated risk factors for arterial thrombosis were available only for three patients who showed, respectively, smoking and dyslipidemia (2 cases) and smoking and intravenous desmopressin infusion (1 case). The majority of patients with venous thrombosis showed DVT with or without PE. Four patients presented with apparently isolated PE. In two instances thrombosis occurred in unusual sites (central retinal vein and portal vein, respectively). Several associated risk factors were present, mainly: infusion of FVIII or FVIII + vWF concentrates in 7 cases; surgery in 8 cases, pregnancy in 1, desmopressin infusion in 1, variable coagulation defects or polymorphisms in 5. More than one of these associated conditions were present in a few patients. The majority of vWD patients who showed thrombotic phenomena were type I patient, but in 6 cases were also type 3. The type of defect was not reported in 6 patients. As a conclusion of this review it seems safe to assume that both arterial and venous thrombosis appear rare in vWD. This is confirmed by the fact that arterial or venous thrombosis appears slightly more frequent in hemophilia A and B.
Collapse
Affiliation(s)
- A Girolami
- Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy.
| | | | | | | | | |
Collapse
|
40
|
Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, Saggiorato G, Steffan A, Damian T, Cella G, Teso S, Manara R, Rampazzo P, Meneghetti G, Basso G, Sartori MT, Sainati L. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One 2013; 8:e78801. [PMID: 24205317 PMCID: PMC3808283 DOI: 10.1371/journal.pone.0078801] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2013] [Accepted: 09/17/2013] [Indexed: 01/15/2023] Open
Abstract
Background Thrombotic complications in Sickle Cell Disease (SCD) arise since infancy, but the role of the coagulation system in children has been poorly explored. To determine its role in the development of clinical complications in childhood we measured coagulation and endothelial parameters in children with SCD at steady state. Methods Markers of thrombin generation, fibrin dissolution and endothelial activation were evaluated in 38 children with SS-Sβ°, 6 with SC disease and 50 age and blood group matched controls. Coagulation variables were correlated with markers of hemolysis and inflammation, with the presence of cerebral and lung vasculopathy and with the frequency of clinical complications. Results SS-Sβ° patients presented higher levels of factor VIII, von Willebrand factor antigen (VWF:Ag) and collagen binding activity, tissue plasminogen activator antigen (t-PA:Ag), D-dimer, p-selectin, prothrombin fragment1+2 (F1+2) and lower ADAMTS-13:activity/VWF:Ag (p<0.05) compared to controls and SC patients. In SS-Sβ° patients coagulation variables correlated positively with markers of inflammation, hemolysis, and negatively with HbF (p<0.05). Patients with cerebral silent infarcts showed significant decrease in t-PA:Ag and ADAMTS-13 Antigen and a tendency toward higher D-dimer, F1+2, TAT compared to patients without them. D-dimer was associated with a six fold increased risk of cerebral silent infarcts. No correlation was found between coagulation activation and large vessel vasculopathy or other clinical events except for decreased t-PA:Ag in patients with tricuspid Rigurgitant Velocity >2.5m/sec. Conclusions SS-Sβ° disease is associated with extensive activation of the coagulation system at steady state since young age. ADAMTS-13 and t-PA:Ag are involved in the development of cerebral silent infarcts.
Collapse
Affiliation(s)
- Raffaella Colombatti
- Clinic of Pediatric Hematology-Oncology, Department of Pediatrics, Azienda Ospedaliera- Università di Padova, Padova, Italy
- * E-mail:
| | - Emiliano De Bon
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Antonella Bertomoro
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Alessandra Casonato
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Elena Pontara
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Elisabetta Omenetto
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Graziella Saggiorato
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Agostino Steffan
- Department of Diagnostic Laboratory and Cellular Therapy, Centro Riferimento Oncologico, Aviano, Italy
| | - Tamara Damian
- Department of Diagnostic Laboratory and Cellular Therapy, Centro Riferimento Oncologico, Aviano, Italy
| | - Giuseppe Cella
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | | | - Renzo Manara
- Neuroradiology Unit, Azienda Ospedaliera-Università di Padova,Padova, Italy
| | - Patrizia Rampazzo
- Neurosonology Unit, Department of Neurological Sciences, Azienda Ospedaliera-Università di Padova,Padova, Italy
| | - Giorgio Meneghetti
- Neurosonology Unit, Department of Neurological Sciences, Azienda Ospedaliera-Università di Padova,Padova, Italy
| | - Giuseppe Basso
- Clinic of Pediatric Hematology-Oncology, Department of Pediatrics, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Maria Teresa Sartori
- Department of Cardiologic, Thoracic and Vascular Sciences, Azienda Ospedaliera- Università di Padova, Padova, Italy
| | - Laura Sainati
- Clinic of Pediatric Hematology-Oncology, Department of Pediatrics, Azienda Ospedaliera- Università di Padova, Padova, Italy
| |
Collapse
|
41
|
Koutroumpi S, Daidone V, Sartori MT, Cattini MG, Albiger NM, Occhi G, Ferasin S, Frigo A, Mantero F, Casonato A, Scaroni C. Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 2013; 16:175-81. [PMID: 22585010 DOI: 10.1007/s11102-012-0398-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A high incidence of venous thromboembolic (VTE) complications has been reported in Cushing's syndrome (CS), mostly post-operatively and attributable to hypercoagulability. The prevalence of symptomatic VTE was investigated retrospectively in 58 consecutive CS patients in relation to acquired and genetic thrombotic risk factors. Eight CS patients (14 %) developed VTE (group A), 3 of them related and 5 unrelated to surgery. These patients had higher urinary free cortisol (p = 0.01) and VWF levels (p = 0.02) than the 50 patients without VTE (group B), as well an increase in the hemostatically more efficient, high-molecular-weight VWF multimers (p = 0.002). Factor V Leiden and the prothrombin gene 20210A variants (the most common inherited thrombophilic defects) were more represented in group A than in group B, as was the genotype GCAG/GCAG of the VWF gene promoter, known to hyperinduce VWF upregulation under cortisol excess. All but one of the patients with VTE unrelated to surgery had at least four acquired and at least one inherited risk factor. Severe hypercortisolism and VWF levels with increased haemostatic activity are strongly associated with VTE in CS. VTE episodes unrelated to surgery are attributable to the synergistic action of acquired and inherited thrombotic risk factors. Based on these observations, we believe that severely affected CS patients should be screened for coagulation disorders and receive antithrombotic prophylaxis whenever they have concomitant prothrombotic risk factors.
Collapse
Affiliation(s)
- S Koutroumpi
- Endocrinology Unit, Department of Medical and Surgical Sciences, University of Padua Medical School, Via Ospedale 105, 35128 Padua, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Casonato A, Pontara E, Battiston M, Morpurgo M, Cattini MG, Casarin E, Saga G, Daidone V, De Marco L. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor. Thromb Haemost 2013; 109:999-1006. [PMID: 23446343 DOI: 10.1160/th12-11-0808] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Accepted: 02/05/2013] [Indexed: 11/05/2022]
Abstract
von Willebrand factor (VWF) multimers result from proteolysis by the metalloprotease ADAMTS13. Since C2362F-VWF features abnormally large multimers with their triplet oligomer structure replaced by a diffuse smear, we explored the susceptibility of C2362F-VWF to ADAMTS13. VWF-enriched blood samples, obtained by cryoethanol precipitation of plasma from a patient with von Willebrand disease (VWD) homozygous for the C2362F mutation and a normal subject, were submitted to cleavage by recombinant ADAMTS13 under static conditions in the presence of urea. C2362F-VWF proved completely ADAMTS13-resistant in vitro. At any concentration of recombinant ADAMTS13 (from 0.1 µM to 1 µM), there was no evidence of the abnormally large VWF multimers of C2362F-VWF disappearing, nor any increased representation of triplet multimer bands, unlike the situation seen in normal VWF. This is due partly to a defective ADAMTS13 binding to C2362F-VWF under static conditions, as seen in both the patient's and recombinant mutated VWF proteins. These findings were associated with a significantly shorter than normal survival of C2362F-VWF after DDAVP, demonstrating that proteolysis and VWF survival may be independent phenomena. Our findings clearly demonstrate that the loss of cysteine 2362 makes VWF resistant to proteolysis by ADAMTS13, at least partly due to an impaired ADAMTS13 binding to VWF. This suggests that the B2 domain of VWF is involved in modulating ADAMTS13 binding to VWF and the consequent proteolytic process. The C2362F-VWF mutation also enables a new abnormality to be identified in the VWF-ADAMTS13 relationship, i.e. an ADAMTS13-resistant VWF.
Collapse
Affiliation(s)
- Alessandra Casonato
- Dept. of Cardiologic, Thoracic and Vascular Sciences, Via Ospedale Civile 105, Padua, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Casonato A, Daidone V, Barbon G, Pontara E, Di Pasquale I, Gallinaro L, Marullo L, Bertorelle G. A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy. Haematologica 2012; 98:147-52. [PMID: 22875612 DOI: 10.3324/haematol.2012.066019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The impaired capacity of von Willebrand factor to carry factor VIII is identified as type 2N von Willebrand's disease. R854Q is the most common type 2N mutation, and almost the only one identified in Italy. This aim of this study was to ascertain whether R854Q mutations in a cohort of Italian patients with type 2N von Willebrand's disease originated from a single event or recurrent events. Thirteen unrelated Italian families were investigated, analyzing the von Willebrand factor gene haplotype associated with the R854Q mutation. A common haplotype emerged in all the families, extending from single nucleotide polymorphisms rs2166902 to rs216293 over 48.2 kb and including five intragenic markers. This haplotype is infrequent in the healthy Italian population (17% versus 100%, P<0.0001) and each genetic marker within the said haplotype is similarly rare. These data strongly suggest a founder effect, with a single R854Q mutation event being the cause of the type 2N von Willebrand's disease in our cohort of patients. Using DMLE+ software and the mathematical model of Bengtsson and Thomson, it was estimated that the R854Q mutation occurred from 10,000 to 40,000 years ago, which is consistent with the short dimension of the haplotype shared by our patients. Together with the fact that the R854Q mutation seems to be limited to Caucasian populations, these findings suggest that a single mutational event took place after human populations moved from Africa towards Europe.
Collapse
Affiliation(s)
- Alessandra Casonato
- Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, France.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin Thromb Hemost 2011; 37:456-63. [PMID: 22102187 DOI: 10.1055/s-0031-1281029] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
One of the more recent findings concerning Von Willebrand disease (VWD) is that a shorter Von Willebrand factor (VWF) survival either decides or modulates the VWD phenotype by downregulating circulating VWF levels. VWF survival is currently investigated with the desmopressin (DDAVP) test, a time-consuming strategy enabling the main pharmacokinetic parameters (e.g., VWF half-life elimination time and clearance) to be defined. An alternative now available involves assaying the VWF propeptide (VWFpp) in single steady-state blood samples, which reportedly increases as VWF survival decreases. This article demonstrates how measuring VWFpp and calculating the VWFpp-to-VWF:antigen ratio (VWFpp ratio) are good alternatives to DDAVP for investigating VWF survival. In type 1 VWD, the VWFpp ratio has been found normal in patients with pure quantitative VWF defects, markedly increased in cases with an isolated decline in VWF survival, and more or less increased in patients with both quantitative defects and a shorter VWF survival. The same applies to type 2B VWD, which is characterized by an increased VWFpp ratio and a shorter VWF survival, with values that appear inversely related. Exploring VWF half-life by assaying VWFpp is useful not only for the more precise characterization of VWD but also for defining its most appropriate treatment.
Collapse
Affiliation(s)
- Alessandra Casonato
- Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy.
| | | | | |
Collapse
|
45
|
Daidone V, Gallinaro L, Grazia Cattini M, Pontara E, Bertomoro A, Pagnan A, Casonato A. An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease. Haematologica 2011; 96:881-7. [PMID: 21393328 DOI: 10.3324/haematol.2010.036848] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Nucleotide variations not changing protein sequences are considered silent mutations; accumulating data suggest that they can, however, be important in human diseases. DESIGN AND METHODS We report an altered splicing process induced by a silent substitution (c.7056C>T) in the von Willebrand factor gene in a case of type 1 von Willebrand disease originally classified as lacking von Willebrand factor mutations. RESULTS The c.7056C>T synonymous substitution introduces a new donor splice site within exon 41, leading to messenger RNA lacking nucleotides 7055-7081 (c.7055_7081del). The encoded von Willebrand factor protein is predicted to lack amino acids 2352-2360 in the B2 domain. The patient's von Willebrand disease phenotype was characterized by reduced plasma and platelet von Willebrand factor, which was normal in function and multimer structure. In vitro expression studies demonstrated that co-transfection of equimolar c.7055_7081del and wild-type von Willebrand factor (mimicking the patient's heterozygous state) induced a 50% lower von Willebrand factor secretion than the wild type, while almost no von Willebrand factor secretion was seen with the mutated von Willebrand factor alone. The secreted von Willebrand factor was structurally and functionally normal, suggesting that the c.7056C>T substitution behaves like a loss-of-function allele. CONCLUSIONS This is the first report of a synonymous von Willebrand factor substitution being responsible for von Willebrand disease. Our findings suggest the need to reconsider the role of von Willebrand factor polymorphisms in von Willebrand disease.
Collapse
Affiliation(s)
- Viviana Daidone
- Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua Medical School, via Ospedale Civile 105, Padova, Italy
| | | | | | | | | | | | | |
Collapse
|
46
|
Lumachi F, Zanella S, Cella G, Casonato A, Fallo F. Endothelial activation markers soluble E-selectin and von Willebrand factor in primary hyperparathyroidism. In Vivo 2011; 25:279-282. [PMID: 21471547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The aim of the study was to investigate the possible alteration of endothelial activity and its reversibility, by the measurement of von Willebrand factor (vWF) and soluble E-selectin (sES) in patients with primary hyperparathyroidism (PHPT), before and after successful parathyroidectomy. Twenty-two patients with confirmed PHPT were prospectively enrolled in the study. Sixteen sex- and age-matched healthy volunteers were used as the control group. The baseline levels of both vWF (146.1 ± 29.1 vs. 118.2 ± 26.3 U/dL, p=0.004) and sES (47.1 ± 19.7 vs. 34.2 ± 13.2 ng/mL, p=0.029) were higher in the patients with PHPT, while at the 6-month follow-up, vWF decreased significantly (120.4 ± 27.3 U/dL, p=0.004) and sES was normal (41.2 ± 21.1 ng/mL, p=NS). No correlation (p=NS) was found between any of the baseline biochemical parameters. In conclusion, some markers of endothelial activation may be higher in patients with PHPT with respect to controls and the decrease of vWF after parathyroidectomy should be considered as a biochemical parameter of improved endothelial function.
Collapse
Affiliation(s)
- Franco Lumachi
- University of Padua, School of Medicine, Department of Surgical & Gastroenterological Sciences, 35128 Padova, Italy.
| | | | | | | | | |
Collapse
|
47
|
Daidone V, Boscaro M, Pontara E, Cattini MG, Occhi G, Scaroni C, Mantero F, Casonato A. New insight into the hypercoagulability of Cushing's syndrome. Neuroendocrinology 2011; 93:121-5. [PMID: 21304226 DOI: 10.1159/000323765] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Accepted: 12/18/2010] [Indexed: 11/19/2022]
Abstract
BACKGROUND Hypercoagulability and a tendency for thromboembolic complications are reported in Cushing's syndrome (CS). The hypercoagulability is due mainly to the cortisol-induced increase in von Willebrand factor (VWF) and factor VIII. This is not a constant feature of CS, however; it depends on particular single nucleotide polymorphism (SNP) haplotypes in the VWF gene promoter: haplotype 1 (-3268G/-2709C/-2661A/-2527G) confers a greater risk of VWF upregulation by cortisol than haplotype 2 (-3268C/ -2709T/-2661G/-2527A). In healthy individuals these SNPs are in linkage disequilibrium with the -2144 (GT)(n) of the VWF promoter: haplotype 1 mainly segregates with short GT repeats (15-19, GTs), haplotype 2 with long repeats (GT ≥ 20, GT(L)). METHODS We analyzed the (GT)(n) locus, the SNP haplotypes and their association with VWF levels in 80 CS patients in order to precisely define the cortisol-sensitive VWF promoter pattern. CS patients were divided into groups A (increased VWF) and B (normal VWF). RESULTS Haplotype 1 and (GT)(S) were more frequent in group A patients, and conferred a 9- and 7.5-fold risk of developing high VWF levels, respectively. Haplotype 2 and (GT)(L) were more represented in group B. There was also an unexpected higher prevalence of recombinant SNP haplotypes in CS patients (6.2%) than in normals (0.9%), p = 0.002. CONCLUSIONS Our results indicate that the cortisol-induced increase in VWF may be predicted by VWF promoter polymorphisms, haplotype 1 and (GT)(S) being the sensitive pattern. These represent new markers for defining the prothrombotic risk of CS. The clinical significance, if any, of the increased recombination rate in SNP haplotypes in the VWF promoter warrants further study.
Collapse
Affiliation(s)
- Viviana Daidone
- Department of Cardiologic, Thoracic and Vascular Sciences, Second Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Daidone V, Pontara E, Romualdi C, Cattini MG, Scaroni C, Albiger N, Pagnan A, Casonato A. Microsatellite (GT)n is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. Thromb Res 2010; 125:e275-80. [DOI: 10.1016/j.thromres.2010.01.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2009] [Revised: 10/22/2009] [Accepted: 01/25/2010] [Indexed: 01/13/2023]
|
49
|
Casonato A, Gallinaro L, Cattini MG, Sartorello F, Pontara E, Padrini R, Bertomoro A, Daidone V, Pagnan A. Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. Transl Res 2010; 155:200-8. [PMID: 20303469 DOI: 10.1016/j.trsl.2009.12.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2009] [Revised: 12/01/2009] [Accepted: 12/02/2009] [Indexed: 10/20/2022]
Abstract
It may be difficult to diagnose type 1 von Willebrand disease (VWD) because of its heterogeneous and sometimes elusive nature. To evaluate the contribution of a shorter von Willebrand factor (VWF) survival in modulating VWD phenotype, the VWF half-life was assessed in 45 type 1 VWD patients using a 24-h 1-desamino-8-d-arginine vasopressin (DDAVP) test. A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance. VWF survival and clearance were normal in patients who carried nonsense mutations. The VWF-propeptide-to-VWF-antigen (VWF:Ag) ratio (VWFpp ratio) was higher in patients with a shorter VWF survival, and the values were inversely correlated with the VWF half-life (P<0.01). The response of VWF to DDAVP administration, which is useful to explore the synthesis and storage of VWF, was normal in patients with no mutations, whereas it decreased in patients with missense and nonsense mutations. Three scenarios, thus, are recognizable in type 1 VWD; one is associated mainly with a shorter survival of VWF, another is associated with its reduced synthesis and release, and a third is characterized by a combination of the two. The shorter VWF half-life found in patients with no VWF mutations suggests that mechanisms other than VWF might be involved in the pathogenesis of type 1 VWD.
Collapse
Affiliation(s)
- Alessandra Casonato
- Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Casonato A, Gallinaro L, Cattini MG, Pontara E, Padrini R, Bertomoro A, Daidone V, Pagnan A. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica 2010; 95:1366-72. [PMID: 20305138 DOI: 10.3324/haematol.2009.019927] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Type 2B von Willebrand factor (VWF) is characterized by gain of function mutations in the A1 domain inducing a greater affinity for platelet GPIb, possibly associated with the disappearance of large VWF multimers and thrombocytopenia. DESIGN AND METHODS VWF survival was explored using 1-desamino-8-D-arginine vasopressin (DDAVP) in 18 patients with type 2B von Willebrand disease (VWD) and compared with their platelet count and large VWF multimer representation. RESULTS A similarly significant shorter VWF survival, expressed as T(1/2)elimination (T(1/2)el), was observed in patients lacking large VWF multimers (type 2B) and in those with a normal multimer pattern (atypical type 2B) (4.47+/-0.41 h and 4.87+/-0.9 h, respectively, vs. normal 15.53+/-2.17 h) due mainly to a greater VWF clearance. The half-life of large VWF multimers, explored by VWF collagen binding (VWF:CB) activity, was likewise reduced. The similarly reduced VWF half-life was also confirmed by the increase in the VWF propeptide ratio (a useful tool for exploring VWF survival) which was found to be the same in type 2B and atypical type 2B patients. The post-DDAVP drop in platelet count occurred in all patients lacking large multimers but not in those with a normal multimer pattern. A correlation was always found between pre- and/or post-DDAVP thrombocytopenia and the lack of large VWF multimers in type 2B VWD while these were unrelated to the reduced VWF half-life. CONCLUSIONS In addition to demonstrating that a shorter VWF survival contributes to the type 2B and atypical type 2B VWD phenotype, our findings suggest that VWF clearance and proteolysis are independent phenomena.
Collapse
Affiliation(s)
- Alessandra Casonato
- Dept. of Cardiologic, Thoracic and Vascular Sciences, Via Ospedale Civile 105, Padua, Italy.
| | | | | | | | | | | | | | | |
Collapse
|